We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $163M
1-Year Est. Return 240.43%
This Fund
S&P 500
This Quarter Est. Return
+40.51%
1 Year Est. Return
+240.43%
3 Year Est. Return
+409.28%
5 Year Est. Return
+142.09%
10 Year Est. Return
+4,071.98%
AUM
$332M
AUM Growth
+$73.4M
Cap. Flow
-$17.1M
Cap. Flow %
-5.15%
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
BOLD
Audentes Therapeutics, Inc
BOLD
+$15.6M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$1.54M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$5.47B
$256M 77.19%
4,205,615
-28,255
-0.7% -$1.54M
VCYT icon
2
Veracyte
VCYT
$3.2B
$33.7M 10.14%
1,205,407
– –
GRTS
3
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$27.8M 8.39%
3,102,929
– –
OCUL icon
4
Ocular Therapeutix
OCUL
$2.19B
$8.75M 2.64%
2,215,384
– –
VANI icon
5
Vivani Medical
VANI
$107M
$3.34M 1.01%
187,207
– –
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
$1.07M 0.32%
543,753
– –
CLVS
7
DELISTED
Clovis Oncology, Inc.
CLVS
$1.06M 0.32%
101,855
– –
BOLD
8
DELISTED
Audentes Therapeutics, Inc
BOLD
– –
-553,916
Closed -$15.6M

Similar funds

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
GF
Gimbal Financial Carmel, Indiana $163M AUM
ACM
Arrington Capital Management Miami, Florida $163M AUM
KFS
Krane Financial Solutions Calabasas, California $162M AUM
VB
Value Base Tel Aviv, Israel $162M AUM 2.31% 1-Year Est. Return
RWA
Reicon Wealth Advisors Atlanta, Georgia $162M AUM
CCM
Candelo Capital Management New York $162M AUM 112.87% 1-Year Est. Return
GCM
Generation Capital Management Pittsford, New York $163M AUM 42.22% 1-Year Est. Return

Versant Venture Management's Q4 2019 Portfolio in Review

As of Q4 2019, Versant Venture Management held 8 positions worth $332M, up 28% from $258M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management withdrew a net $17.1M in Q4 2019, closing 1 position and reducing 1 holding. Its most notable exit was Audentes Therapeutics, Inc, an estimated $15.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Versant Venture Management's biggest Q4 2019 reduction was CRISPR Therapeutics, cutting an estimated $1.54M.
  • Versant Venture Management fully exited Audentes Therapeutics, Inc in Q4 2019, selling an estimated $15.6M.
  • Versant Venture Management's ten largest holdings make up 100% of its $332M portfolio in Q4 2019.
  • Versant Venture Management opened 0 new positions and closed 1 in Q4 2019.
  • Versant Venture Management's portfolio value rose 28% quarter-over-quarter to $332M.

Based on Versant Venture Management's 13F filing for Q4 2019, filed 21 Jan 2020.